What problem does this paper attempt to address?

The problem that this paper attempts to solve is the prediction of the response to intravenous glucocorticoid (IVGC) treatment in thyroid eye disease (TED). Specifically, the paper proposes a new method - Whole - orbit radiomics (WOR). Through multi - organ segmentation (MOS) and fused - organ segmentation (FOS) strategies, combined with machine - learning algorithms, high - throughput quantitative features are extracted from orbital magnetic resonance imaging (MRI) to construct a prediction model, so as to improve the prediction accuracy of the response to IVGC treatment. ### Background - **Thyroid eye disease (TED)**: This is a common autoimmune orbital disease, affecting 25 - 40% of Graves' disease patients and other thyroid disease patients. According to the immune status and disease course, TED can be divided into the active stage and the inactive stage. Lesions develop in all orbital soft tissues. - **Intravenous glucocorticoid (IVGC)**: It is the first - line treatment for active and moderate - to - severe TED, with strong anti - inflammatory effects, but there are risks of side effects such as hypertension, hyperglycemia, and osteoporosis. - **Clinical activity score (CAS)**: It is used to assess the activity of TED, but its predictive effect is limited because it only records the ocular inflammatory manifestations and subjective pain, ignoring the pathological changes in the posterior orbit. ### Limitations of existing methods - **Traditional semi - quantitative imaging models**: Based on the signal intensity ratio (SIR) of T2 - weighted imaging (T2WI) or other simple indicators, the prediction effect is limited. - **Single - region radiomics (SRR)**: It only focuses on a single organ (such as the extraocular muscles), failing to fully utilize the image information. ### Solutions - **Multi - organ segmentation (MOS)**: Manually segment multiple structures within the orbit, including the extraocular muscles (EOMs), lacrimal gland (LG), orbital fat (OF), and optic nerve (ON), and extract features respectively. - **Fused - organ segmentation (FOS)**: Consider the above - mentioned structures as a whole unit and extract features. - **Multi - region radiomics (MRR) and fused - region radiomics (FRR) models**: Use six machine - learning algorithms (support vector machine SVM, logistic regression LR, Naive Bayes, extreme random tree ExtraTrees, XGBoost, LightGBM) to construct prediction models. ### Main results - **MRR model**: The SVM classifier performs best in the MRR model, with an AUC value reaching 0.961. - **FRR model**: The LR classifier performs best in the FRR model, with an AUC value reaching 0.916. - **Comparison**: The MRR model is significantly superior to the SRR model and the traditional semi - quantitative imaging model. ### Conclusions - The **Whole - orbit radiomics (WOR) model** performs excellently in predicting the response to IVGC treatment. By including more orbital structures and applying machine - learning algorithms, it improves the accuracy and robustness of the prediction model. - **MOS and FOS strategies** bring new prospects for radiomics research on orbital diseases and other diseases.

Whole-orbit radiomics: machine learning-based multi- and fused- region radiomics signatures for intravenous glucocorticoid response prediction in thyroid eye disease

Prediction of treatment response to intravenous glucocorticoid in patients with thyroid-associated ophthalmopathy using T2 mapping and T2 IDEAL

Radiomics Analysis of Contrast-Enhanced CT for the Preoperative Prediction of Microvascular Invasion in Mass-Forming Intrahepatic Cholangiocarcinoma

An MRI-based joint model of radiomics and spatial distribution differentiates autoimmune encephalitis from low-grade diffuse astrocytoma

Predicting the response to glucocorticoid therapy in thyroid-associated ophthalmopathy: mobilizing structural MRI-based quantitative measurements of orbital tissues

Prediction models of intravenous glucocorticoids therapy response in thyroid eye disease

T2‐Weighted MR Imaging‐Derived Radiomics for Pretreatment Determination of Therapeutic Response to Glucocorticoid in Patients with Thyroid‐Associated Ophthalmopathy: Comparison with Semiquantitative Evaluation

Texture analysis of orbital magnetic resonance imaging for monitoring and predicting treatment response to glucocorticoids in patients with thyroid-associated ophthalmopathy

Predicting glucocorticoid effectiveness in thyroid eye disease: combined value from serological lipid metabolism and orbital MRI parameter

OCT Radiomic Features Used for the Assessment of Activity of Thyroid Eye Disease

Whole-orbit-based multiparametric assessment of disease activity of thyroid eye disease on Dixon MRI

Predicting Glucocorticoid Effectiveness in Thyroid Eye Disease: Combined Value from Serological Lipid Metabolism and an Orbital MRI Parameter.

Determining Disease Activity and Glucocorticoid Response in Thyroid-Associated Ophthalmopathy: Preliminary Study Using Dynamic Contrast-Enhanced MRI

Radiomics analysis of T1WI and T2WI magnetic resonance images to differentiate between IgG4-related ophthalmic disease and orbital MALT lymphoma

T2 Mapping with and without Fat-Suppression to Predict Treatment Response to Intravenous Glucocorticoid Therapy for Thyroid-Associated Ophthalmopathy

Use of extreme gradient boosting, light gradient boosting machine, and deep neural networks to evaluate the activity stage of extraocular muscles in thyroid-associated ophthalmopathy

Diagnostic precision in thyroid-associated ophthalmopathy using multi-center radiomics with 99mTc-DTPA SPECT/CT

Prediction of early recurrence of adult-type diffuse gliomas following radiotherapy using multi-modal magnetic resonance images

Predicting delayed remission in Cushing's disease using radiomics models: a multi-center study

Combining radiomics with thyroid imaging reporting and data system to predict lateral cervical lymph node metastases in medullary thyroid cancer

Baseline Volumetric T2 Relaxation Time Histogram Analysis: Can It Be Used to Predict the Response to Intravenous Methylprednisolone Therapy in Patients With Thyroid-Associated Ophthalmopathy?